Current Oncology Enters an Exciting New Chapter in 2021


Current Oncology, Canada’s premier cancer research journal, proudly conceived and published by Multimed Inc. for over 27 years, is changing hands. Multimed has agreed to sell the Journal to MDPI, a multinational publishing firm, with the primary goal of sharing the impact of its’ scholarly research with a broad global audience.

With almost 300 journal titles in its portfolio, the Multidisciplinary Digital Publishing Institute (MDPI), based in Basel, Switzerland, is well positioned to lead Current Oncology in this next important chapter. With over 24 years of experience, MDPI is the largest open access publisher and one of the fastest growing academic publishers world-wide.

Multimed Inc., is proud of the accomplishments and forever grateful for the tireless efforts of its past and current editorial leaders. Your dedication and commitment in the field of oncology research has set a high bar for those that follow in this next iteration of Current Oncology. You left an indelible mark that garnered the attention and respect of academics, scholars, and oncologists that has truly made us proud.

Over the many years, Multimed’s team was indefatigable in our effort to continuously improve and grow the Journal to where it is today. Evidenced in 2018 when Current Oncology received the notable achievement of being accepted into MEDLINE, the premier bibliographic database with more than 26 million references to journal articles. This could not have occurred without our talented team and growing recognition as experts in open access publishing.

Multimed will publish Current Oncology for the final two issues in 2020 and continue to focus our attention on growing the current portfolio of open-access, scientific, peer-reviewed scholarly journals for the foreseeable future.